Anlotinib, which is a novel oral multitarget receptor tyrosine kinase inhibitor, was first approved as the third-line treatment for refractory advanced non-small-cell lung cancer in May 2018 [18]. Here, NTRK1 is linked to non-small cell lung carcinoma.